Janux Therapeutics Inc (JANX)
47.11
-0.40
(-0.84%)
USD |
NASDAQ |
May 17, 16:00
47.11
0.00 (0.00%)
After-Hours: 20:00
Janux Therapeutics Cash and Short Term Investments (Quarterly): 651.76M for March 31, 2024
Cash and Short Term Investments (Quarterly) Chart
Historical Cash and Short Term Investments (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 651.76M |
| December 31, 2023 | 344.03M |
| September 30, 2023 | 349.71M |
| June 30, 2023 | 303.29M |
| March 31, 2023 | 316.88M |
| December 31, 2022 | 327.02M |
| September 30, 2022 | 338.76M |
| Date | Value |
|---|---|
| June 30, 2022 | 354.30M |
| March 31, 2022 | 361.20M |
| December 31, 2021 | 374.96M |
| September 30, 2021 | 387.51M |
| June 30, 2021 | 394.20M |
| March 31, 2021 | 70.77M |
| December 31, 2020 | 7.813M |
Cash and Short Term Investments Definition
Cash and Short Term investments is the sum of two balance sheet line items: cash and equivalents and short term investments in marketable securities.
Cash and Short Term Investments (Quarterly) Range, Past 5 Years
7.813M
Minimum
Dec 2020
651.76M
Maximum
Mar 2024
327.30M
Average
346.87M
Median
Cash and Short Term Investments (Quarterly) Benchmarks
| Viking Therapeutics Inc | 962.98M |
| Equillium Inc | 32.28M |
| Minerva Neurosciences Inc | 34.82M |
| Arvinas Inc | 1.169B |
| Calidi Biotherapeutics Inc | 1.949M |